Comprehensive Stock Comparison
Compare Windtree Therapeutics, Inc. (WINT) vs Amarin Corporation plc (AMRN) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Quality / Margins | AMRN | -38.0% net margin vs WINT's -454.0% |
| Stability / Safety | AMRN | Beta 0.84 vs WINT's 0.92, lower leverage |
| Dividends | WINT | 100.0% yield; 1-year raise streak; AMRN pays no meaningful dividend |
| Momentum (1Y) | AMRN | +27.3% vs WINT's -99.7% |
| Efficiency (ROA) | AMRN | -13.1% ROA vs WINT's -255.6%, ROIC -18.7% vs -144.7% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Windtree Therapeutics is a clinical-stage biopharmaceutical company developing novel therapies for acute cardiovascular and pulmonary conditions. It generates revenue primarily through research collaborations and licensing agreements while advancing its pipeline—including istaroxime for heart failure and KL4 surfactant products for respiratory distress—toward commercialization. The company's key advantage lies in its proprietary KL4 surfactant technology platform and its focus on acute care conditions with significant unmet medical needs.
Amarin Corporation is a pharmaceutical company focused on developing and commercializing cardiovascular therapeutics. It generates nearly all its revenue from VASCEPA — a prescription omega-3 fatty acid product for reducing triglyceride levels — sold primarily to wholesalers and specialty pharmacies. Its key advantage is patent protection and regulatory exclusivity for VASCEPA, though this moat faces challenges from generic competition.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
AMRN leads in 4 of 6 categories — strongest in Financial Metrics and Profitability & Efficiency. 1 category is tied.
Financial Metrics (TTM)
AMRN is the larger business by revenue, generating $227M annually — 2519.3x WINT's $90,000. AMRN is the more profitable business, keeping -38.0% of every revenue dollar as net income compared to WINT's -454.0%.
| Metric | WINTWindtree Therapeu… | AMRNAmarin Corporatio… |
|---|---|---|
| RevenueTrailing 12 months | $90,000 | $227M |
| EBITDAEarnings before interest/tax | -$14M | -$93M |
| Net IncomeAfter-tax profit | -$41M | -$86M |
| Free Cash FlowCash after capex | -$15M | -$22M |
| Gross MarginGross profit ÷ Revenue | +12.2% | +38.9% |
| Operating MarginEBIT ÷ Revenue | -151.3% | -42.5% |
| Net MarginNet income ÷ Revenue | -454.0% | -38.0% |
| FCF MarginFCF ÷ Revenue | -168.0% | -9.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +17.4% |
| EPS Growth (YoY)Latest quarter vs prior year | +99.5% | +69.7% |
Valuation Metrics
| Metric | WINTWindtree Therapeu… | AMRNAmarin Corporatio… |
|---|---|---|
| Market CapShares × price | $336,342 | $5.7B |
| Enterprise ValueMkt cap + debt − cash | $379,342 | $5.6B |
| Trailing P/EPrice ÷ TTM EPS | -0.00x | -3.45x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 25.11x |
| Price / BookPrice ÷ Book value/share | 0.00x | 0.58x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
AMRN delivers a -18.8% return on equity — every $100 of shareholder capital generates $-19 in annual profit, vs $-4540 for WINT. AMRN carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to WINT's 0.18x.
| Metric | WINTWindtree Therapeu… | AMRNAmarin Corporatio… |
|---|---|---|
| ROE (TTM)Return on equity | -4539.6% | -18.8% |
| ROA (TTM)Return on assets | -2.6% | -13.1% |
| ROICReturn on invested capital | -144.7% | -18.7% |
| ROCEReturn on capital employed | -99.0% | -17.0% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 2 |
| Debt / EquityFinancial leverage | 0.18x | 0.02x |
| Net DebtTotal debt minus cash | $43,000 | -$113M |
| Cash & Equiv.Liquid assets | $2M | $121M |
| Total DebtShort + long-term debt | $2M | $8M |
| Interest CoverageEBIT ÷ Interest expense | -106.46x | -7085.14x |
Total Returns (with DRIP)
A $10,000 investment in AMRN five years ago would be worth $1,115 today (with dividends reinvested), compared to $0 for WINT. Over the past 12 months, AMRN leads with a +27.3% total return vs WINT's -99.7%. The 3-year compound annual growth rate (CAGR) favors AMRN at -30.2% vs WINT's -98.7% — a key indicator of consistent wealth creation.
| Metric | WINTWindtree Therapeu… | AMRNAmarin Corporatio… |
|---|---|---|
| YTD ReturnYear-to-date | -66.7% | +0.6% |
| 1-Year ReturnPast 12 months | -99.7% | +27.3% |
| 3-Year ReturnCumulative with dividends | -100.0% | -66.0% |
| 5-Year ReturnCumulative with dividends | -100.0% | -88.9% |
| 10-Year ReturnCumulative with dividends | -100.0% | -52.7% |
| CAGR (3Y)Annualised 3-year return | -98.7% | -30.2% |
Risk & Volatility
AMRN is the less volatile stock with a 0.84 beta — it tends to amplify market swings less than WINT's 0.92 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. AMRN currently trades 66.0% from its 52-week high vs WINT's 0.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | WINTWindtree Therapeu… | AMRNAmarin Corporatio… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.92x | 0.84x |
| 52-Week HighHighest price in past year | $3.54 | $20.90 |
| 52-Week LowLowest price in past year | $0.01 | $7.08 |
| % of 52W HighCurrent price vs 52-week peak | +0.3% | +66.0% |
| RSI (14)Momentum oscillator 0–100 | 25.8 | 40.0 |
| Avg Volume (50D)Average daily shares traded | 323K | 76K |
Analyst Outlook
WINT is the only dividend payer here at 100.00% yield — a key consideration for income-focused portfolios.
| Metric | WINTWindtree Therapeu… | AMRNAmarin Corporatio… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Hold |
| Price TargetConsensus 12-month target | — | $2.17 |
| # AnalystsCovering analysts | — | 18 |
| Dividend YieldAnnual dividend ÷ price | +100.0% | — |
| Dividend StreakConsecutive years of raises | 1 | — |
| Dividend / ShareAnnual DPS | $12.49 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Mar 20 | Feb 26 | Change |
|---|---|---|---|
| Windtree Therapeuti… (WINT) | 100 | 0 | -100.0% |
| Amarin Corporation … (AMRN) | 100 | 4.66 | -95.3% |
Amarin Corporation … (AMRN) returned -89% over 5 years vs Windtree Therapeuti… (WINT)'s -100%.
Chart 2Revenue Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| Windtree Therapeuti… (WINT) | $987000.00 | $0.00 | -100.0% |
| Amarin Corporation … (AMRN) | $82M | $229M | +179.6% |
Windtree Therapeutics, Inc.'s revenue grew from $1M (2015) to $0M (2024) — a -100.0% CAGR. Amarin Corporation plc's revenue grew from $82M (2015) to $229M (2024) — a 12.1% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| Windtree Therapeuti… (WINT) | -55.9% | -138.8% | -148.2% |
| Amarin Corporation … (AMRN) | -140.9% | -35.9% | +74.5% |
Amarin Corporation plc's net margin went from -141% (2015) to -36% (2024).
Chart 4EPS Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| Windtree Therapeuti… (WINT) | -999,999 | -104.35 | +100.0% |
| Amarin Corporation … (AMRN) | -16.6 | -4 | +75.9% |
Windtree Therapeutics, Inc.'s EPS grew from $-999999.00 (2015) to $-104.35 (2024). Amarin Corporation plc's EPS grew from $-16.60 (2015) to $-4.00 (2024).
Chart 5Free Cash Flow — 5 Years
Windtree Therapeutics, Inc. generated $-15M FCF in 2024 (+36% vs 2021). Amarin Corporation plc generated $-31M FCF in 2024 (+53% vs 2021).
WINT vs AMRN: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is WINT or AMRN a better buy right now?
Analysts rate Amarin Corporation plc (AMRN) a "Hold" — based on 18 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — WINT or AMRN?
Over the past 5 years, Amarin Corporation plc (AMRN) delivered a total return of -88.9%, compared to -100.0% for Windtree Therapeutics, Inc. (WINT). A $10,000 investment in AMRN five years ago would be worth approximately $1K today (assuming dividends reinvested). Over 10 years, the gap is even starker: AMRN returned -52.7% versus WINT's -100.0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — WINT or AMRN?
By beta (market sensitivity over 5 years), Amarin Corporation plc (AMRN) is the lower-risk stock at 0.84β versus Windtree Therapeutics, Inc.'s 0.92β — meaning WINT is approximately 9% more volatile than AMRN relative to the S&P 500. On balance sheet safety, Amarin Corporation plc (AMRN) carries a lower debt/equity ratio of 2% versus 18% for Windtree Therapeutics, Inc. — giving it more financial flexibility in a downturn.
04Which has better profit margins — WINT or AMRN?
Amarin Corporation plc (AMRN) is the more profitable company, earning -35.9% net margin versus -454.0% for Windtree Therapeutics, Inc. — meaning it keeps -35.9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AMRN leads at -40.2% versus -151.3% for WINT. At the gross margin level — before operating expenses — AMRN leads at 35.6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — WINT or AMRN?
In this comparison, WINT (100.0% yield) pays a dividend. AMRN does not pay a meaningful dividend and should not be held primarily for income.
06Is WINT or AMRN better for a retirement portfolio?
For long-horizon retirement investors, Windtree Therapeutics, Inc. (WINT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.92), 100.0% yield). Both have compounded well over 10 years (WINT: -100.0%, AMRN: -52.7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between WINT and AMRN?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. In terms of investment character: WINT is a small-cap income-oriented stock; AMRN is a small-cap quality compounder stock. WINT pays a dividend while AMRN does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.